2816-LB: Efficacy and Safety of Oral Ribupatide (HRS9531) in Adults with Obesity: A Phase 2 Trial
Abstract
Introduction and Objective: Ribupatide is a GLP-1/GIP receptor dual agonist peptide. QW injection of ribupatide demonstrated compelling weight loss in a Phase 3 trial. This study evaluated the efficacy and safety of oral ribupatide in adults with obesity and no diabetes. Methods: Participants (pts) with a BMI of 28−40 kg/m2 were randomized 1:1:1:1 to receive oral ribupatide (10, 25, or 50 mg) or placebo (PBO) for 26 weeks. The primary endpoint was the percentage change in body weight from baseline at W26. Results: The mean baseline body weight and BMI were 92.6 kg and 33.3 kg/m2. Based on treatment policy estimand at W26, LS mean weight loss from baseline were 6.7%, 11.9%, and 11.4% for ribupatide 10, 25, and 50 mg, compared to 2.1% for PBO (p=0.0023, p
Fields of Study & Subjects
Diabetes Treatment and Management
Bariatric Surgery and Outcomes
Diet and metabolism studies
Publication details
- Journal / source
- Diabetes
- Publisher
- American Diabetes Association
- Volume
- 75
- Issue
- Supplement_1
- Publication date
- 5 June 2026
- Language
- EN